Quince lays off 47% of staff, stakes sale sign for asset days after separate pipeline deal

Quince Therapeutics is laying off nearly half of its staff and looking to out-license a preclinical asset almost immediately after selling a portion of its pipeline to Lighthouse Pharmaceuticals.